Publications by authors named "F Benedini"

Aim: We reviewed the clinical features of a sample of pediatric acquired demyelinating syndromes with the purpose of determining the appropriate protocol for follow-up after the first episode.

Methods: A multicenter retrospective observational study was conducted on a cohort of 40 children diagnosed with a first episode of acquired demyelinating syndrome over the period 2012-2021. Patients were evaluated with clinical and neuroradiologic assessment after 3, 6, and 12 months, with a median follow-up of 4.

View Article and Find Full Text PDF

Several aromatic/heterocyclic sulfonamide scaffolds have been used to synthesize compounds incorporating NO-donating moieties of the nitrate ester type, which have been investigated for the inhibition of five physiologically relevant human carbonic anhydrase (hCA, EC 4.2.1.

View Article and Find Full Text PDF
Article Synopsis
  • Novel compounds combining nitric oxide-releasing features with a dorzolamide scaffold were created and tested for their ability to inhibit carbonic anhydrase (CA) enzymes, particularly hCA II.
  • Different synthesized compounds showed varying potency levels in inhibiting these enzymes, with compound 8 demonstrating a strong binding affinity confirmed by X-ray crystal structure analysis.
  • Compounds 4, 6, and 8 not only effectively relaxed blood vessels but also significantly lowered intraocular pressure in normotensive rabbits, indicating their potential use in treating hypertensive glaucoma.
View Article and Find Full Text PDF

Organic nitrates, such as nitroglycerin, have been used in clinical practice for more than one century for the treatment of angina, even before the identification of Nitric Oxide (NO) as the so-called Endothelium Derived Relaxing Factor (EDRF). Recently, multiple functions of this molecule in biology and pathophysiology have been discovered and alterations in the NO signalling pathway have often been associated with disease progression in mammals, providing a strong rationale for the use of NO as a potential drug. To have a therapeutic benefit from NO properties, an elegant approach has been designed coupling well-known existing drugs with moieties able to slowly release NO following enzymatic metabolism.

View Article and Find Full Text PDF

NO-donating aspirin (NO-ASA), a novel pharmacological agent currently undergoing clinical testing, consists of ASA to which a nitrate group is covalently linked via a spacer molecule. We synthesized the three positional isomers of NO-ASA with respect to the -CH(2)ONO(2) group (ortho, meta, and para) and examined whether this isomerism affects the biological activity of NO-ASA on HT-29 human colon cancer cells. The ortho- and para-isomers showed similar IC(50) values (1-5 microM) for cell growth inhibition over 72 h, whereas the IC(50) of the meta-isomer was 200 to 500 microM.

View Article and Find Full Text PDF